Insulin therapy: Unmet needs and new perspectives

Minerva Endocrinologica

Volumn 38, Issue 1, 2013, Pages 95-102

  Giordano, C ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Hypoglycemia; Insulin; Pharmacology

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN GLARGINE;

ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC RETINOPATHY; DIET THERAPY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY FAILURE; KINESIOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; REVIEW; SELF CARE;

BIOLOGICAL MARKERS; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; TREATMENT OUTCOME;

EID: 84876525567     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
2. ISTAT. Annuario statistico italiano 2010 [Internet]. Available at http://wwwistatit/dati/catalogo/20101119-00/PDF/cap3pdf [cited 2013, Jan 30].
3. Unger J, Parkin C. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med 2011;123.81-91.
4. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007;30:1241-7.
5. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S et al. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 2007;38:1154-60.
6. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR et at. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
8. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a metaanalysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009;19:604-12.
9. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycemia an aggravating factor? Diabetes Metab Res Rev 2008;24:353-63.
10. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
11. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycemia in type 2 diabetes. Diabet Med 2008;25:245-54.
12. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993,329:977-86.
13. Simons WR, Vinod HD, Gerber RA, Bolinder B. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycemic control and diabetes-related complications? A German population-based study. Exp Clin Endocrinol Diabetes 2006;114:520-6.
14. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40.
15. Peyrot M, Barnett AH, Meneghini LF, SchummDraeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-9.
16. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5.
17. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009:6-10.
18. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5.
19. Randlov J, Poulsen JU. How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study. J Diabetes Sci Technol 2008;2:229-35.
20. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12.
21. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29:2104-14.
22. Kalra S, Unnikrishnan AG, Baruah M, Kalra B. Degludec insulin: a novel basal insulin. Indian J Endocrinol Metab 2011;15:S12-6.
23. Kurtzhals P, Heise T, Strauss H. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose lowering effect of insulin degludec. American Diabetes Association 71st Scientific Session 2011.
24. Heise T, Hovelmann U, Nosek L. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. American Diabetes Association 71st Scientific Session 2011.
25. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64.
26. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-97.
27. Meneghini L, Atkin S, Bain S. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in eople with type 2 diabetes. American Diabetes Association 71st Scientific Session 2011.
28. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-507.
29. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011;377:924-31.